Survey Results

USA
Canada

In-person and remote meetings between doctors & pharma companies now standard

Since its initial onset, COVID-19 has had a significant impact on how physicians interact with pharmaceutical companies. Government restrictions forced companies to quickly adapt and move to more remote forms of interactions. While in-person interactions are once again a viable option for communication, will they return to pre-pandemic levels? MD Analytics has been monitoring these trends over the past few years and we have recently interviewed 50 Canadian GPs and 90 Canadian specialists in our latest survey on the topic....

USA
Canada

Are remote consults here to stay?

With COVID-19 about to enter its 3rd year, it continues to significantly impact the lives of Canadians and the practices of HCPs in the country. Even though it has not been easy, physicians have continuously adapted how they manage their patients and how they interact with key healthcare stakeholders during the pandemic. MD Analytics has been monitoring these trends over the past few years and we have recently interviewed 140 physicians in our latest survey on the topic....

USA
Canada

Physician Interest and Participation in Market Research

Market research plays a fundamental role in helping those involved in the healthcare market answer key questions about their brands. Gaining insights from healthcare practitioners is central to market research. However, engaging physicians to participate in research can be a challenge. While most of the surveyed physicians say they enjoy participating in market research studies, in practice, physicians self-report participating in less than half of the number of studies they are invited to participate in. Real-world experience from our panel says the response rate is even lower. With this in mind, we asked Canadian physicians to help us understand what...

USA
Canada

Discover How Physicians Want to Learn About New Treatments

Engaging prescribers is a key component to the launch of any new brand. But what are the key components that drive interest for physicians in learning more? Overall, physicians express greater satisfaction when learning about new products through in person interactions compared to virtual or digital interactions. However, regardless of how they learn about new product, the types of resources physicians prefer are similar. The top most preferred resources for both GPs and Specialists include presentation at conferences, discussions with peers, educational events that include KOLs or treatment areas experts, presentations by lead authors, journal clubs and discussions with Pharmaceutical...

USA
Canada

Understanding the Impact of COVID-19 on New Pharma Product Launches

The COVID-19 pandemic had a significant impact on physicians, including how they learn about and integrate new products into their practice. While not all saw a decline, close to 1 in 3 Specialists and close to half of GPs say their use of newly launched products declined during the pandemic, primarily due to a lack of pharma presence, reduced patient volumes overall and just a general lack of comfort using new products....

the performance of patient support providers during the pandemic splash image
USA
Canada

The Performance of Patient Support Providers During The Pandemic

We surveyed 152 physicians in the U.S. to gauge their opinions on Patient Support Program (PSPs) providers during the pandemic. Physicians surveyed include GPs, Hematologists, Medical Oncologists, Rheumatologists, Pulmonologists, Endocrinologists and Infectious Disease Specialists. Overall perceptions of PSPs compared to before the pandemic have generally improved – especially in terms of responsiveness and the expertise of individuals working on PSPs....

pandemic impact on patient support programs splash image
USA
Canada

Pandemic Impact On Patient Support Programs

PSPs play a significant role in ensuring that patients have the best possible experience during their journey – especially in specialty therapeutic areas where treatments tend to be more expensive. The pandemic has made it more challenging for patients to access support and services for their medical conditions. This has put additional pressure on company-sponsored PSPs to further enhance their offerings to help patients in the best way possible. PSPs have become increasingly important for patients since the onset of the COVID-19 pandemic and as a result now have an even more significant influence on physicians’ treatment selection process. For...

COVID-19_Impact_PSP_B_splash_image_900x500
USA
Canada

How Patient Support Program Providers Adjusted To The Pandemic

Physicians feel positive about how Patient Support Programs (PSPs) have evolved in the past two years – especially in terms of responsiveness and the expertise of individuals working on PSPs. The main unmet needs at this time remain the range of service hours and the availabilityof nurses remotely (either by phone or virtually). Many specialists believe that biosimilar PSP providers have struggled more than originator drug PSPs since the onset of the pandemic – mainly because of they do not have as many employees and offer a smaller range of services....

COVID-19 impact on patient support programs splash image
USA
Canada

COVID-19 Impact on Patient Support Programs

Patient Support Programs (PSPs) play a significant role in ensuring that patients have the best possible experience during their journey – especially in specialty therapeutic areas where treatments tend to be more expensive. The COVID-19 pandemic has made it more challenging for patients to access support and services for their medical conditions. This has put additional pressure on company-sponsored PSPs to further enhance their offerings to help patients in the best way possible. PSPs have become increasingly important for patients since the onset of the COVID-19 pandemic and as a result now have an even more significant influence on physicians’...

HCPs more than a year into COVID-19 splash image
USA
Canada

How COVID-19 is affecting HCPs as vaccinations take hold

As the COVID-19 vaccination campaign ramped up in the Spring, and rates of infection dropped, a return to normality appeared to be on the horizon. However, with widespread vaccine hesitancy paired with the virulent spread of the delta variant, we are once again left with an uncertain view of the future. Throughout the past year, MD Analytics has been monitoring the effects of this uncertainty, and the pandemic in general, on the practices and perceptions of HCPs. Ongoing changes in workloads, patient assessments, and interactions with pharma have had direct and meaningful impact on the healthcare industry....

CTA

We are here to answer your questions.

Ready to explore how data-driven insights can accelerate your pharmaceutical research? Connect with our team to discuss your goals.